Cambridge Investment Research Advisors
RXRX icon

Cambridge Investment Research Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
61,553
-7,367
-11% -$24.5K ﹤0.01% 3711
2026
Q1 		$212K Sell
68,920
-5,038
-7% -$19.5K ﹤0.01% 3633
2025
Q4 		$302K Sell
73,958
-67,123
-48% -$332K ﹤0.01% 3199
2025
Q3 		$688K Buy
141,081
+13,832
+11% +$72.6K ﹤0.01% 2369
2025
Q2 		$644K Buy
127,249
+10,129
+9% +$49.8K ﹤0.01% 2318
2025
Q1 		$620K Buy
117,120
+29,136
+33% +$212K ﹤0.01% 2243
2024
Q4 		$595K Buy
87,984
+8,401
+11% +$56.5K ﹤0.01% 2277
2024
Q3 		$524K Buy
79,583
+2,615
+3% +$18.7K ﹤0.01% 2374
2024
Q2 		$577K Buy
76,968
+6,858
+10% +$59.8K ﹤0.01% 2182
2024
Q1 		$699K Buy
70,110
+6,114
+10% +$68.1K ﹤0.01% 1993
2023
Q4 		$631K Buy
63,996
+4,157
+7% +$29.6K ﹤0.01% 2002
2023
Q3 		$458K Buy
+59,839
New +$597K ﹤0.01% 2153

Other funds holding RXRX

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM

Cambridge Investment Research Advisors's RXRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 11% in Q2 2026, selling an estimated $24.5K and leaving 61,553 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.

Cambridge Investment Research Advisors first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $699K in Q1 2024. 88 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cambridge Investment Research Advisors held 61,553 shares of Recursion Pharmaceuticals worth $226K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 7,367 Recursion Pharmaceuticals shares in Q2 2026, an estimated $24.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3711 holding.
  • Cambridge Investment Research Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Cambridge Investment Research Advisors's Recursion Pharmaceuticals position peaked at $699K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.